Filing Flows › Integrated Biopharma (INBP) › Q3 FY26 › vs Q2 FY26
Integrated Biopharma (INBP) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Integrated Biopharma's revenue fell $1.2M (-10%) from $11.3M in Q2 FY26 to $10.1M in Q3 FY26. The biggest changes: Contract Manufacturing −$1.1M (-10%); Other Nutraceutical Business −$76K (-21%).
Integrated Biopharma, Q3 FY26: revenue $10.1M (-28% year over year), operating margin -10.7%, net loss $837K, operating cash flow $517K. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Contract Manufacturing | $9.8M | $10.9M | −$1.1M | -10% |
| Other Nutraceutical Business | $284K | $360K | −$76K | -21% |
| Revenue | $10.1M | $11.3M | −$1.2M | -10% |
| Other income, net | $50K | $40K | $10K | +25% |
| Income tax benefit | $198K | $112K | $86K | +77% |
| Net loss | $837K | $762K | $75K | +10% |
| Costs & expenses | $11.2M | $12.2M | −$1.0M | -8% |
| Operating costs | $11.2M | $12.2M | −$1.0M | -8% |
| Operating cash sources | $1.4M | $1.4M | −$25K | -2% |
| Depreciation | $68K | $78K | −$10K | -13% |
| Share-based compensation | $50K | $42K | $8K | +19% |
| Working capital & other | $1.2M | $1.3M | −$23K | -2% |
| Net loss absorbed | $837K | $762K | $75K | +10% |
| Operating cash flow | $517K | $617K | −$100K | -16% |
Questions
How much did Integrated Biopharma's revenue grow quarter over quarter in Q3 FY26?
Integrated Biopharma's revenue fell $1.2M (-10%) from $11.3M in Q2 FY26 to $10.1M in Q3 FY26.
What drove Integrated Biopharma's revenue change in Q3 FY26?
Contract Manufacturing −$1.1M (-10%); Other Nutraceutical Business −$76K (-21%).